Chimerix - CMRX Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings or view top-rated stocks.

3 brokerages have issued 1 year price targets for Chimerix's shares. Their CMRX share price forecasts range from $6.00 to $11.00. On average, they predict the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 367.0% from the stock's current price.
View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts.

Chimerix's stock was trading at $1.86 at the start of the year. Since then, CMRX shares have decreased by 2.2% and is now trading at $1.82.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our CMRX earnings forecast.

Chimerix, Inc. (NASDAQ:CMRX) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The biopharmaceutical company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.39 million. Chimerix had a net margin of 464.75% and a trailing twelve-month return on equity of 147.04%. During the same quarter last year, the business posted ($0.18) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD).

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Chimerix's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Monaco Asset Management SAM (2.62%), Allspring Global Investments Holdings LLC (0.43%), Assenagon Asset Management S.A. (0.30%), Strs Ohio (0.09%), Mission Wealth Management LP (0.04%) and Envestnet Asset Management Inc. (0.03%). Insiders that own company stock include David Jakeman, Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends.

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CMRX stock can currently be purchased for approximately $1.82.

Chimerix (NASDAQ:CMRX) has a market capitalization of $160.23 million and generates $1.98 million in revenue each year. The biopharmaceutical company earns $-173,240,000.00 in net income (profit) each year or $1.75 on an earnings per share basis.

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146.